Can a second drug stop the body from rejecting arthritis treatment?

NCT ID NCT01895764

Completed Disease control Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether adding methotrexate to adalimumab (a biologic drug) reduces the chance that the body makes antibodies against adalimumab in people with ankylosing spondylitis. About 110 adults with active disease who did not respond well to NSAIDs took part. The goal was to see if the combination helps the biologic stay effective longer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANKYLOSING SPONDYLITIS

Contacts and locations

Locations

Médecine polyvalente, CH de SAINT NAZAIRE

Saint-Nazaire, 44606, France
Rhumatologie / IPROS, CHR d'ORLEANS

Orléans, 45032, France
Rhumatologie, CH de BLOIS

Blois, 41000, France
Rhumatologie, CH de SAINT BRIEUC

Saint-Brieuc, 22027, France
Rhumatologie, CHD LA ROCHE SUR YON

La Roche-sur-Yon, 85925, France
Rhumatologie, CHR du MANS

Le Mans, 72037, France
Rhumatologie, CHRU de BREST

Brest, 29609, France
Rhumatologie, CHRU de NANTES

Nantes, 44093, France
Rhumatologie, CHRU de POITIERS

Poitiers, 86021, France
Rhumatologie, CHRU de RENNES

Rennes, 35203, France
Rhumatologie, CHRU de TOURS

Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.